OA05.02 Analysis of Resistance Mmechanisms to Pralsetinib in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) from the ARROW Study

Chromosomal rearrangements involving the RET receptor tyrosine kinase are validated oncogenic drivers in 1–2% of patients with NSCLC. Pralsetinib is a selective RET tyrosine kinase inhibitor that has demonstrated clinical activity in patients with NSCLC harboring a RET fusion. Here, we report potential mechanisms of resistance in patients with NSCLC whose disease progressed on pralsetinib.